PT - JOURNAL ARTICLE AU - Butzner, Michael AU - Leslie, Douglas AU - Cuffee, Yendelela AU - Hollenbeak, Christopher S AU - Sciamanna, Christopher AU - Abraham, Theodore P TI - Sex differences in clinical outcomes for obstructive hypertrophic cardiomyopathy in the USA: a retrospective observational study of administrative claims data AID - 10.1136/bmjopen-2021-058151 DP - 2022 Mar 01 TA - BMJ Open PG - e058151 VI - 12 IP - 3 4099 - http://bmjopen.bmj.com/content/12/3/e058151.short 4100 - http://bmjopen.bmj.com/content/12/3/e058151.full SO - BMJ Open2022 Mar 01; 12 AB - Objectives To evaluate sex differences in demographic and clinical characteristics, treatments and outcomes for patients with diagnosed obstructive hypertrophic cardiomyopathy (oHCM) in the USA.Setting Retrospective observational study of administrative claims data from MarketScan Commercial Claims and Encounters Database from IBM Watson Health.Participants Of the 28 million covered employees and family members in MarketScan, 9306 patients with oHCM were included in this analysis.Main outcome measures oHCM-related outcomes included heart failure, atrial fibrillation, ventricular tachycardia/ fibrillation, sudden cardiac death, septal myectomy, alcohol septal ablation (ASA) and heart transplant.Results Among 9306 patients with oHCM, the majority were male (60.5%, p<0.001) and women were of comparable age to men (50±15 vs 49±15 years, p<0.001). Women were less likely to be prescribed beta blockers (42.7% vs 45.2%, p=0.017) and undergo an implantable cardioverter-defibrillator (1.7% vs 2.6%, p=0.005). Septal reduction therapy was performed slightly more frequently in women (ASA: 0.08% vs 0.05%, p=0.600; SM: 0.35% vs 0.18%, p=0.096), although not statistically significant. Women were less likely to have atrial fibrillation (6.7% vs 9.9%, p<0.001).Conclusion Women were less likely to be prescribed beta blockers, ACE inhibitors, anticoagulants, undergo implantable cardioverter-defibrillator and have ventricular tachycardia/fibrillation. Men were more likely to have atrial fibrillation. Future research using large, clinical real-world data are warranted to understand the root cause of these potential treatment disparities in women with oHCM.No data are available.